Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30, 2025

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29, 2025

The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Biosimilars Oncology Roundup for June 2024—Podcast Edition

July 7th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

Samsung Bioepis’ Ustekinumab Biosimilar Demonstrates PK Equivalence in Healthy Adults

July 6th 2024

By Deana Ferreri, PhD

Article

A phase 1 study demonstrated pharmacokinetic (PK) bioequivalence of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the EU- and US-sourced reference products.

The Top 5 Biosimilar Articles for the Week of July 1

July 5th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 1, 2024.

Eye on Pharma: New Data, Clinical Developments, and Biosimilar Partnerships

July 4th 2024

By Skylar Jeremias

Article

As Celltrion publishes phase 3 data on its tocilizumab biosimilar, other companies finalize partnerships, and Formycon begins development for a pembrolizumab biosimilar.

Biosimilars Oncology Roundup: June 2024

July 2nd 2024

By Skylar Jeremias

Article

As the weather heats up for the US and Europe, so too did the biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.

Ahzantive Receives FDA Approval as New Eylea Biosimilar

July 1st 2024

By Skylar Jeremias

Article

The FDA has approved Ahzantive (aflibercept-mrbb) as the third biosimilar referencing Eylea (aflibercept) for the treatment of eye conditions, including age-related macular degeneration.

FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara

July 1st 2024

By Skylar Jeremias

Article

Pyzchiva (ustekinumab-ttwe) is the third ustekinumab biosimilar to receive approval for the American market. It was also approved with interchangeability.

BioRationality: FDA Removes Additional Testing for Interchangeable Status of Biosimilars

July 1st 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, champions the FDA's updated guidance to remove switching study data for companies seeking to obtain an interchangeability designation for their biosimilars.

Jeffrey Casberg of IPD Analytics Gives Insight on Specialty Drugs in the Pipeline

June 30th 2024

By Cameron Santoro

Video

In an interview with Jeffrey Casberg, MS, RPh, he discusses 3 promising specialty drugs coming through the pipeline. Casberg explains these drugs offer new treatment options for major diseases and stakeholders should watch for their potential impact on the market.

Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD

June 29th 2024

By Deana Ferreri, PhD

Article

Two phase 3 trials in patients with inflammatory bowel disease (IBD) found higher clinical remission rates in those treated with the subcutaneous formulation of infliximab biosimilar CT-P13 compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.